How can survival be improved in localized osteosarcoma?

References

• Rosenburg SA, Chabner BA, Young RC et al. Treatment of osteogenic sarcoma. I. Effect of adjuvant high-dose methotrexate after amputation. Cancer Treat. Rep.63(5), 739–751 (1979).
   PubMedGoogle Scholar
• Campanacci M, Bacci G, Bertoni F et al. The treatment of osteosarcoma of the extremities: twenty year’s experience at the Istituto Ortopedico Rizzoli. Cancer48(7), 1569–1581 (1981).
   PubMed Web of Science ®Google Scholar
• Rosen G, Marcove RC, Caparros B et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer43(6), 2163–2177 (1979).
   PubMed Web of Science ®Google Scholar
• Rosen G, Tan C, Sanmaneechai A et al. The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma. Cancer35(3 Suppl.), 936–945 (1975).
   PubMed Web of Science ®Google Scholar
• Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep.63(11–12), 1727–1733 (1979).
   PubMedGoogle Scholar
• DeVita VT Jr. Progress in cancer management. Keynote address. Cancer51(12 Suppl.), 2401–2409 (1983).
   PubMed Web of Science ®Google Scholar
• Malawer MM, Link MP, Donaldson SS. Sarcoma of bone: chemotherapy for bone sarcomas. In: Cancer: Principle and Practice of Oncology. DeVita VT Jr, Hellman S, Rosenberg SA (Eds). Lippincott–Raven, PA, USA 1804–1811 (1997).
   Google Scholar
• Goorin AM, Schwartzentruber DJ, Devidas M et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J. Clin. Oncol.21(8), 1574–1580 (2003).
   PubMed Web of Science ®Google Scholar
• Bielack SS, Kempf-Bielack B, Delling G et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J. Clin. Oncol.20(3), 776–790 (2002).
   PubMed Web of Science ®Google Scholar
• Meyers PA, Heller G, Healey J et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan–Kettering experience. J. Clin. Oncol.10(1), 5–15 (1992).
   PubMed Web of Science ®Google Scholar
• Rosen G, Caparros B, Huvos AG et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer49(6), 1221–1230 (1982).
   PubMed Web of Science ®Google Scholar
• Bacci G, Picci P, Ferrari S et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer72(11), 3227–3238 (1993).
   PubMed Web of Science ®Google Scholar
• Provisor AJ, Ettinger LJ, Nachman JB et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J. Clin. Oncol.15(1), 76–84 (1997).
   PubMed Web of Science ®Google Scholar
• Winkler K, Beron G, Delling G et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J. Clin. Oncol.6(2), 329–337 (1988).
   PubMed Web of Science ®Google Scholar
• Saeter G, Alvegard TA, Elomaa I et al. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J. Clin. Oncol.9(10), 1766–1775 (1991).
   PubMed Web of Science ®Google Scholar
• Meyers PA, Gorlick R, Heller G et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan–Kettering (T12) protocol. J. Clin. Oncol.16(7), 2452–2458 (1998).
   PubMed Web of Science ®Google Scholar
• Smeland S, Muller C, Alvegard TA et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur. J. Cancer39(4), 488–494 (2003).
   PubMed Web of Science ®Google Scholar
• Souhami RL, Craft AW, Van der Eijken JW et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet350(9082), 911–917 (1997).
   PubMed Web of Science ®Google Scholar
• Eselgrim M, Grunert H, Kuhne T et al. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatr. Blood Cancer47(1), 42–50 (2006).
   PubMed Web of Science ®Google Scholar
• Le Deley MC, Guinebretiere JM, Gentet JC et al. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur. J. Cancer43(4), 752–761 (2007).
   PubMed Web of Science ®Google Scholar
• Fuchs N, Bielack SS, Epler D et al. Long-term results of the co-operative German–Austrian–Swiss Osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann. Oncol.9(8), 893–899 (1998).
   PubMed Web of Science ®Google Scholar
• Bacci G, Ferrari S, Longhi A et al. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J. Chemother.14(2), 198–206 (2002).
   PubMed Web of Science ®Google Scholar
• Ferrari S, Smeland S, Mercuri M et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J. Clin. Oncol.23(34), 8845–8852 (2005).
   PubMed Web of Science ®Google Scholar
• Meyers PA, Schwartz CL, Krailo MD et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the Children’s Oncology Group. J. Clin. Oncol.26(4), 633–638 (2008).
   PubMed Web of Science ®Google Scholar
• Leu KM, Ostruszka LJ, Shewach D et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J. Clin. Oncol.22(9), 1706–1712 (2004).
   PubMed Web of Science ®Google Scholar
• Navid F, Willert JR, McCarville MB et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer113(2), 419–425 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson PM, Wiseman GA, Erlandson L et al. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin. Cancer Res.11(19 Pt 1), 6895–6900 (2005).
   PubMed Web of Science ®Google Scholar
• O’Day K, Gorlick R. Novel therapeutic agents for osteosarcoma. Expert Rev. Anticancer Ther.9(4), 511–523 (2009).
   PubMed Web of Science ®Google Scholar
• Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev. Anticancer Ther.6(7), 1075–1085 (2006).
   PubMed Web of Science ®Google Scholar
• Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (DOXIL) in sarcoma. Cancer Invest.21(2), 167–176 (2003).
   PubMed Web of Science ®Google Scholar
• Jaffe N. Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat. Res.152, 239–262 (2010).
   Google Scholar
• Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat. Rev. Cancer3(9), 685–694 (2003).
   PubMed Web of Science ®Google Scholar
• Maloney EK, McLaughlin JL, Dagdigian NE et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res.63(16), 5073–5083 (2003).
   PubMed Web of Science ®Google Scholar
• Kolb EA, Gorlick R, Houghton PJ et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr. Blood Cancer50(6), 1190–1197 (2008).
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Manara MC, Nicoletti G et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res.65(9), 3868–3876 (2005).
   PubMed Web of Science ®Google Scholar
• Lopaczynski W, Terry C. Insulin-like growth factor I activates insulin receptor substrate 1 and Ras in human osteosarcoma cells. Acta Biochim. Pol.46(1), 117–123 (1999).
   PubMed Web of Science ®Google Scholar
• Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res.65(6), 2406–2411 (2005).
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Morton CL, Kolb EA et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr. Blood Cancer50(4), 799–805 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang P, Yang Y, Zweidler-McKay PA, Hughes DP. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin. Cancer Res.14(10), 2962–2969 (2008).
   PubMedGoogle Scholar
• Kaya M, Wada T, Akatsuka T et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin. Cancer Res.6(2), 572–577 (2000).
   PubMed Web of Science ®Google Scholar
• Kaya M, Wada T, Kawaguchi S et al. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br. J. Cancer86(6), 864–869 (2002).
   PubMed Web of Science ®Google Scholar
• Wittenburg LA, Bisson L, Rose BJ, Korch C, Thamm DH. The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin. Cancer Chemother. Pharmacol. DOI: 10.1007/s00280-010-1287-z (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Hudson M, Jaffe MR, Jaffe N et al. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J. Clin. Oncol.8(12), 1988–1997 (1990).
   PubMed Web of Science ®Google Scholar
• Bacci G, Longhi A, Bertoni F et al. Primary high-grade osteosarcoma: comparison between preadolescent and older patients. J. Pediatr. Hematol. Oncol.27(3), 129–134 (2005).
   PubMedGoogle Scholar
• Ferrari S, Bertoni F, Mercuri M et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann. Oncol.12(8), 1145–1150 (2001).
   PubMed Web of Science ®Google Scholar
• Lee JA, Kim MS, Kim DH et al. Osteosarcoma developed in the period of maximal growth rate have inferior prognosis. J. Pediatr. Hematol. Oncol.30(6), 419–424 (2008).
   PubMedGoogle Scholar
• Carsi B, Rock MG. Primary osteosarcoma in adults older than 40 years. Clin. Orthop. Relat. Res. (397), 53–61 (2002).
   PubMedGoogle Scholar
• Jeon DG, Lee SY, Cho WH, Song WS, Park JH. Primary osteosarcoma in patients older than 40 years of age. J. Korean Med. Sci.21(4), 715–718 (2006).
   PubMed Web of Science ®Google Scholar
• Bacci G, Ferrari S, Mercuri M et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41–60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999. Acta Orthop.78(3), 377–384 (2007).
   PubMed Web of Science ®Google Scholar
• Harting MT, Lally KP, Andrassy RJ et al. Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients. J. Cancer Res. Clin. Oncol.136(4), 561–570 (2010).
   PubMedGoogle Scholar
• Song WS, Kong CB, Jeon DG et al. Prognosis of extremity osteosarcoma in patients aged 40–60 years: a cohort/case controlled study at a single institute. Eur. J. Surg. Oncol.36(5), 483–488 (2010).
   PubMedGoogle Scholar
• Kawai A, Huvos AG, Meyers PA, Healey JH. Osteosarcoma of the pelvis. Oncologic results of 40 patients. Clin. Orthop. Relat. Res.348, 196–207 (1998).
   Google Scholar
• Ozaki T, Flege S, Kevric M et al. Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J. Clin. Oncol.21(2), 334–341 (2003).
   PubMed Web of Science ®Google Scholar
• Daecke W, Bielack S, Martini AK et al. Osteosarcoma of the hand and forearm: experience of the Cooperative Osteosarcoma Study Group. Ann. Surg. Oncol.12(4), 322–331 (2005).
   PubMedGoogle Scholar
• Bramer JA, van Linge JH, Grimer RJ, Scholten RJ. Prognostic factors in localized extremity osteosarcoma: a systematic review. Eur. J. Surg. Oncol.35(10), 1030–1036 (2009).
   PubMed Web of Science ®Google Scholar
• Cho WH, Song WS, Jeon DG et al. Differential presentations, clinical courses, and survivals of osteosarcomas of the proximal humerus over other extremity locations. Ann. Surg. Oncol.17(3), 702–708 (2010).
   PubMed Web of Science ®Google Scholar
• Haworth JM, Watt I, Park WM, Roylance J. Diaphyseal osteosarcoma. Br. J. Radiol.54(647), 932–938 (1981).
   PubMedGoogle Scholar
• Sim FH, Frassica FJ, Unni KK. Osteosarcoma of the diaphysis of long bones: clinicopathologic features and treatment of 51 cases. Orthopedics18(1), 19–23 (1995).
   PubMedGoogle Scholar
• Kong CB, Kim MS, Lee SY et al. Prognostic effect of diaphyseal location in osteosarcoma: a cohort case–control study at a single institute. Ann. Surg. Oncol.16(11), 3094–3100 (2009).
   PubMedGoogle Scholar
• Bieling P, Rehan N, Winkler P et al. Tumor size and prognosis in aggressively treated osteosarcoma. J. Clin. Oncol.14(3), 848–858 (1996).
   PubMed Web of Science ®Google Scholar
• Kim MS, Lee SY, Cho WH et al. An examination of the efficacy of the 8 cm maximal tumor diameter cutoff for the subdivision of AJCC stage II osteosarcoma patients. J. Surg. Oncol.98(6), 427–431 (2008).
   PubMed Web of Science ®Google Scholar
• Bacci G, Longhi A, Versari M et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer106(5), 1154–1161 (2006).
   PubMed Web of Science ®Google Scholar
• Lindner NJ, Ramm O, Hillmann A et al. Limb salvage and outcome of osteosarcoma. The University of Muenster experience. Clin. Orthop. Relat. Res. (358), 83–89 (1999).
   PubMedGoogle Scholar
• Kim MS, Lee SY, Cho WH et al. Initial tumor size predicts histologic response and survival in localized osteosarcoma patients. J. Surg. Oncol.97(5), 456–461 (2008).
   PubMed Web of Science ®Google Scholar
• Jaffe N, Spears R, Eftekhari F et al. Pathologic fracture in osteosarcoma. Impact of chemotherapy on primary tumor and survival. Cancer59(4), 701–709 (1987).
   PubMed Web of Science ®Google Scholar
• Bramer JA, Abudu AA, Grimer RJ, Carter SR, Tillman RM. Do pathological fractures influence survival and local recurrence rate in bony sarcomas? Eur. J. Cancer43(13), 1944–1951 (2007).
   PubMed Web of Science ®Google Scholar
• Bacci G, Ferrari S, Longhi A et al. Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation: local and systemic control by amputation or limb salvage after preoperative chemotherapy. Acta Orthop. Scand.74(4), 449–454 (2003).
   PubMed Web of Science ®Google Scholar
• Kim MS, Lee SY, Lee TR et al. Prognostic effect of pathologic fracture in localized osteosarcoma: a cohort/case controlled study at a single institute. J. Surg. Oncol.100(3), 233–239 (2009).
   PubMedGoogle Scholar
• Scully SP, Ghert MA, Zurakowski D, Thompson RC, Gebhardt MC. Pathologic fracture in osteosarcoma: prognostic importance and treatment implications. J. Bone Joint Surg. Am.84-A(1), 49–57 (2002).
   Google Scholar
• Hauben EI, Weeden S, Pringle J, Van Marck EA, Hogendoorn PC. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur. J. Cancer38(9), 1218–1225 (2002).
   PubMed Web of Science ®Google Scholar
• Bacci G, Bertoni F, Longhi A et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer97(12), 3068–3075 (2003).
   PubMed Web of Science ®Google Scholar
• Kim MS, Cho WH, Song WS, Lee SY, Jeon DG. Time dependency of prognostic factors in patients with stage II osteosarcomas. Clin. Orthop. Relat. Res.463, 157–165 (2007).
   PubMedGoogle Scholar
• Hauben EI, Bielack S, Grimer R et al. Clinico–histologic parameters of osteosarcoma patients with late relapse. Eur. J. Cancer42(4), 460–466 (2006).
   PubMedGoogle Scholar
• Brouns F, Stas M, De Wever I. Delay in diagnosis of soft tissue sarcomas. Eur. J. Surg. Oncol.29(5), 440–445 (2003).
   PubMedGoogle Scholar
• Clark MA, Thomas JM. Delay in referral to a specialist soft-tissue sarcoma unit. Eur. J. Surg. Oncol.31(4), 443–448 (2005).
   PubMedGoogle Scholar
• Rougraff BT, Davis K, Lawrence J. Does length of symptoms before diagnosis of sarcoma affect patient survival? Clin. Orthop. Relat. Res.462, 181–189 (2007).
   PubMedGoogle Scholar
• Saithna A, Pynsent PB, Grimer RJ. Retrospective analysis of the impact of symptom duration on prognosis in soft tissue sarcoma. Int. Orthop.32(3), 381–384 (2008).
   PubMed Web of Science ®Google Scholar
• Widhe B, Widhe T. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J. Bone Joint Surg. Am.82(5), 667–674 (2000).
   PubMed Web of Science ®Google Scholar
• Ayerza MA, Muscolo DL, Aponte-Tinao LA, Farfalli G. Effect of erroneous surgical procedures on recurrence and survival rates for patients with osteosarcoma. Clin. Orthop. Relat. Res.452, 231–235 (2006).
   PubMedGoogle Scholar
• Kim MS, Lee SY, Cho WH et al. Prognostic effect of inadvertent curettage without treatment delay in osteosarcoma. J. Surg. Oncol.100(6), 484–487 (2009).
   PubMedGoogle Scholar
• Kim MS, Lee SY, Cho WH et al. Prognostic effects of doctor-associated diagnostic delays in osteosarcoma. Arch. Orthop. Trauma Surg.129(10), 1421–1425 (2009).
   PubMedGoogle Scholar
• Bacci G, Picci P, Ferrari S et al. Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer71(4), 1224–1230 (1993).
   PubMed Web of Science ®Google Scholar
• Bacci G, Longhi A, Ferrari S et al. Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncol. Rep.9(1), 171–175 (2002).
   PubMedGoogle Scholar
• Foukas AF, Deshmukh NS, Grimer RJ et al. Stage-IIB osteosarcomas around the knee. A study of MMP-9 in surviving tumour cells. J. Bone Joint Surg. Br.84(5), 706–711 (2002).
   PubMedGoogle Scholar
• Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J. Cancer Res. Clin. Oncol.134(3), 281–297 (2008).
   PubMed Web of Science ®Google Scholar
• Laverdiere C, Hoang BH, Yang R et al. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin. Cancer Res.11(7), 2561–2567 (2005).
   PubMed Web of Science ®Google Scholar
• Khanna C, Wan X, Bose S et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat. Med.10(2), 182–186 (2004).
   PubMed Web of Science ®Google Scholar
• Ferrari S, Zanella L, Alberghini M et al. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma. 50(4), 752–756 (2008).
   Google Scholar
• Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J. Clin. Oncol.12(2), 423–431 (1994).
   PubMed Web of Science ®Google Scholar
• Bacci G, Mercuri M, Longhi A et al. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur. J. Cancer41(14), 2079–2085 (2005).
   PubMed Web of Science ®Google Scholar
• Salzer-Kuntschik M, Brand G, Delling G. [Determination of the degree of morphological regression following chemotherapy in malignant bone tumors]. Pathologe4(3), 135–141 (1983).
   PubMed Web of Science ®Google Scholar
• Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch. Pathol. Lab. Med.101(1), 14–18 (1977).
   PubMed Web of Science ®Google Scholar
• Picci P, Bacci G, Campanacci M et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer56(7), 1515–1521 (1985).
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst.92(3), 205–216 (2000).
   PubMed Web of Science ®Google Scholar
• Onikul E, Fletcher BD, Parham DM, Chen G. Accuracy of MR imaging for estimating intraosseous extent of osteosarcoma. AJR Am. J. Roentgenol.167(5), 1211–1215 (1996).
   PubMedGoogle Scholar
• Kim MS, Lee SY, Cho WH et al. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients. Ann. Surg. Oncol.15(3), 906–914 (2008).
   PubMedGoogle Scholar
• Dyke JP, Panicek DM, Healey JH et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology228(1), 271–278 (2003).
   PubMed Web of Science ®Google Scholar
• Soderlund V, Larsson SA, Bauer HC et al. Use of 99mTc-MIBI scintigraphy in the evaluation of the response of osteosarcoma to chemotherapy. Eur. J. Nucl. Med.24(5), 511–515 (1997).
   PubMedGoogle Scholar
• Cheon GJ, Kim MS, Lee JA et al. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI. J. Nucl. Med.50(9), 1435–1440 (2009).
   PubMed Web of Science ®Google Scholar
• Hawkins DS, Rajendran JG, Conrad EU 3rd, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer94(12), 3277–3284 (2002).
   PubMed Web of Science ®Google Scholar
• Franzius C, Bielack S, Flege S et al. Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma. J. Nucl. Med.43(8), 1012–1017 (2002).
   PubMed Web of Science ®Google Scholar
• Bacci G, Ferrari S, Delepine N et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J. Clin. Oncol.16(2), 658–663 (1998).
   PubMed Web of Science ®Google Scholar
• Bacci G, Ferrari S, Bertoni F et al. Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy. Clin. Orthop. Relat. Res.386, 186–196 (2001).
   Google Scholar
• Bacci G, Loro L, Longhi A et al. No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma. Anticancer Drugs17(4), 411–415 (2006).
   PubMedGoogle Scholar
• Schwartz CL, Gorlick R, Teot L et al. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children’s Oncology Group. J. Clin. Oncol.25(15), 2057–2062 (2007).
   PubMed Web of Science ®Google Scholar
• Baldini N, Scotlandi K, Barbanti-Brodano G et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N. Engl. J. Med.333(21), 1380–1385 (1995).
   PubMed Web of Science ®Google Scholar
• Gorlick R, Huvos AG, Heller G et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J. Clin. Oncol.17(9), 2781–2788 (1999).
   PubMed Web of Science ®Google Scholar
• Ifergan I, Meller I, Issakov J, Assaraf YG. Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity. Cancer98(9), 1958–1966 (2003).
   PubMed Web of Science ®Google Scholar
• Man TK, Chintagumpala M, Visvanathan J et al. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res.65(18), 8142–8150 (2005).
   PubMed Web of Science ®Google Scholar
• Lee JA, Kim MS, Kim DH et al. Risk stratification based on the clinical factors at diagnosis is closely related to the survival of localized osteosarcoma. Pediatr. Blood Cancer52(3), 340–345 (2009).
   PubMedGoogle Scholar
• Bacci G, Ferrari S, Forni C et al. The effect of intra-arterial versus intravenous cisplatinum in the neoadjuvant treatment of osteosarcoma of the limbs: the experience at the Rizzoli Institute. Chir. Organi Mov.81(4), 369–382 (1996).
   PubMedGoogle Scholar
• Wilkins RM, Cullen JW, Camozzi AB, Jamroz BA, Odom L. Improved survival in primary nonmetastatic pediatric osteosarcoma of the extremity. Clin. Orthop. Relat. Res.438, 128–136 (2005).
   PubMedGoogle Scholar
• Tsuchiya H, Tomita K, Mori Y et al. Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma. Anticancer Res.18(1B), 657–666 (1998).
   PubMed Web of Science ®Google Scholar
• Lewis IJ, Nooij MA, Whelan J et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized Phase III trial of the European Osteosarcoma Intergroup. J. Natl Cancer Inst.99(2), 112–128 (2007).
   PubMed Web of Science ®Google Scholar
• Lawrence JA, Babyn PS, Chan HS et al. Extremity osteosarcoma in childhood: prognostic value of radiologic imaging. Radiology189(1), 43–47 (1993).
   PubMedGoogle Scholar
• Holscher HC, Bloem JL, Vanel D et al. Osteosarcoma: chemotherapy-induced changes at MR imaging. Radiology182(3), 839–844 (1992).
   PubMed Web of Science ®Google Scholar
• Shin KH, Moon SH, Suh JS, Yang WI. Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. Clin. Orthop. Relat. Res.376, 200–208 (2000).
   Google Scholar
• Kim MS, Lee SY, Cho WH et al. Effect of increases in tumor volume after neoadjuvant chemotherapy on the outcome of stage II osteosarcoma regardless of histological response. J. Orthop. Sci.14(3), 292–297 (2009).
   PubMedGoogle Scholar
• Briccoli A, Rocca M, Salone M et al. Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer104(8), 1721–1725 (2005).
   PubMed Web of Science ®Google Scholar
• Grimer RJ, Sommerville S, Warnock D et al. Management and outcome after local recurrence of osteosarcoma. Eur. J. Cancer41(4), 578–583 (2005).
   PubMed Web of Science ®Google Scholar
• Bacci G, Forni C, Longhi A et al. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J. Surg. Oncol.96(2), 118–123 (2007).
   PubMed Web of Science ®Google Scholar
• Gorlick R, Meyers PA. Osteosarcoma necrosis following chemotherapy: innate biology versus treatment-specific. J. Pediatr. Hematol. Oncol.25(11), 840–841 (2003).
   PubMed Web of Science ®Google Scholar